From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Azilsartan mepixetil is the antagonist of angiotensinIIreceptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
AngiotensinII human- 13C6, 15N TFA (Ang II- 13C6, 15N TFA) is 13C- and 15N-labeled AngiotensinII human (TFA) (HY-13948B). AngiotensinII human (AngiotensinII) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions .
AngiotensinII (AngiotensinII) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human also induces apoptosis. AngiotensinII induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII human (AngiotensinII) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human acetate also induces apoptosis. AngiotensinII human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII antipeptide, a peptide, is an inverse agonist of AR1 receptor. AngiotensinII antipeptide is encoded by mRNA, complementary to that encoding AngiotensinII (HY-13948) itself .
AngiotensinII human (AngiotensinII) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human TFA also induces apoptosis. AngiotensinII human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
(Sar1)-AngiotensinII, an analogue of AngiotensinII, is a specific agonist of angiotensin AT1 receptor. (Sar1)-AngiotensinII binds to brain membrane-rich particles, with a Kd of 2.7 nM. (Sar1)-AngiotensinII can stimulate protein synthesis and cell growth in embryonic chick myocytes .
Losartan-d4 is the deuterium labeled Losartan. Losartan is an angiotensinIIreceptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d3 Carboxylic Acid is the deuterium labeled Losartan. Losartan is an angiotensinIIreceptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
(Sar1,Ile4,8)-AngiotensinII is a functionally selective angiotensinII type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-AngiotensinII potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-AngiotensinII potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .
Losartan-d2 is the deuterium labeled Losartan[1]. Losartan is an angiotensinIIreceptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d9 is the deuterium labeled Losartan[1]. Losartan is an angiotensinIIreceptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
AngiotensinII (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensinII . AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
Losartan potassium (DuP-753 potassium) is an angiotensinIIreceptor type 1 (AT1) antagonist, competing with the binding of angiotensinII to AT1 with an IC50 of 20 nM.
AngiotensinII (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
AngiotensinII (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
Saralasin ([Sar1,Ala8] AngiotensinII) acetate hydrate is an octapeptide analog of angiotensinII. Saralasin acetate hydrate is a competitive angiotensinIIreceptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
Saralasin ([Sar1,Ala8] AngiotensinII) is an octapeptide analog of angiotensinII. Saralasin is a competitive angiotensinIIreceptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
Eprosartan mesylate (SKF-108566J) is a selective, competitive, nonpeptid and orally active angiotensinIIreceptor antagonist, used as an antihypertensive. Eprosartan mesylate binds angiotensinIIreceptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively .
Losartan (potassium) (Standard) is the analytical standard of Losartan (potassium). This product is intended for research and analytical applications. Losartan potassium (DuP-753 potassium) is an angiotensinIIreceptor type 1 (AT1) antagonist, competing with the binding of angiotensinII to AT1 with an IC50 of 20 nM.
Saralasin ([Sar1,Ala8] AngiotensinII) TFA is an octapeptide analog of angiotensinII. Saralasin TFA is a competitive angiotensinIIreceptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensinIIreceptor antagonist, used as an antihypertensive. Eprosartan binds angiotensinIIreceptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively .
Aclerastide (DSC-127) is an angiotensinreceptor agonist. Aclerastide also is a peptide analog of angiotensinII. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers .
Eprosartan-d3 is the deuterium labeled Eprosartan. Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensinIIreceptor antagonist, used as an antihypertensive. Eprosartan binds angiotensinIIreceptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively [1].
Valsartan Ethyl Ester is an impurity of Valsartan. Valsartan is an angiotensinIIreceptor antagonist for the treatment of high blood pressure and heart failure .
Eprosartan (mesylate) (Standard) is the analytical standard of Eprosartan (mesylate). This product is intended for research and analytical applications. Eprosartan mesylate (SKF-108566J) is a selective, competitive, nonpeptid and orally active angiotensinIIreceptor antagonist, used as an antihypertensive. Eprosartan mesylate binds angiotensinIIreceptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively .
Buloxibutid (AT2 receptor agonist C21) is a agentlike selective angiotensinII AT2 receptor agonist with Ki values of 0.4 nM and >10 μM for the AT2 receptor and AT1 receptor, respectively .
EMD 66684 is an antagonist of AngiotensinII Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang IIreceptor with an IC50 value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant - .
Azilsartan medoxomil monopotassium is an orally administered angiotensinIIreceptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.
Dehydro Olmesartan is a derivative of Olmesartan. Olmesartan is an angiotensinIIreceptor (AT1R) antagonist and has the potential for high blood pressure study .
Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Irbesartan-d6 is the deuterium labeled Irbesartan. Irbesartan is a highly potent and specific angiotensinII type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
Olmesartan lactone impurity is a cyclic ester impurity of Olmesartan. Olmesartan is an angiotensinIIreceptor (AT1R) antagonist and has the potential for high blood pressure study .
Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensinIIreceptor antagonist and has the potential for high blood pressure and heart failure research[1].
Antihypertensive agent 3 (compound 4a) is an antagonis of angiotensinIIreceptor 1. Antihypertensive agent 3 exhibits antihypertensive activity in a spontaneously hypertensive rats (SHRs) model .
Olmesartan impurity is an Olmesartan impurity. Olmesartan (RNH-6270) is an angiotensinIIreceptor (AT1R) antagonist has the potential for high blood pressure study .
Olmesartan ethyl ester (compound 11) is an Olmesartan impurity. Olmesartan (RNH-6270) is an angiotensinIIreceptor (AT1R) antagonist used to in the high blood pressure study .
Valsartan-d8 is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensinIIreceptor antagonist and has the potential for high blood pressure and heart failure research[1].
BMS-248360 is a potent and orally active dual antagonist of both angiotensinIIreceptor (AT1) and endothelin A (ETA) receptor, with Kis of 10 nM and 1.9 nM for hAT1 and hETA receptor, respectively. BMS-248360 displays hypertensive effects .
Azilsartan medoxomil (TAK 491) is an orally administered angiotensinIIreceptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension .
Nitrosoglutathione (GSNO), a exogenous NO donor and a substrate for rat alcohol dehydrogenase class III isoenzyme, inhibits cerebrovascular angiotensinII-dependent and -independent AT1 receptor responses .
(Rac)-Valsartan-d9 is deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensinIIreceptor antagonist and has the potential for high blood pressure and heart failure research[1].
TRV055, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensinIIreceptor type 1 (AT1R). TRV055 is efficacious in stimulating cellular Gq-mediated signaling .
TRV055 hydrochloride, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensinIIreceptor type 1 (AT1R). TRV055 hydrochloride is efficacious in stimulating cellular Gq-mediated signaling .
Valsartan-d3 is the deuterium labeled Valsartan[1]. Valsartan (CGP 48933) is an angiotensinIIreceptor antagonist and has the potential for high blood pressure and heart failure research[2].
Valsartan (Standard) is the analytical standard of Valsartan. This product is intended for research and analytical applications. Valsartan (CGP 48933) is an angiotensinIIreceptor antagonist and has the potential for high blood pressure and heart failure research .
Sparsentan-d5 is deuterium labeled Sparsentan. Sparsentan (RE-021) is a highly potent dual angiotensinII and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively[1].
Telmisartan (Standard) is the analytical standard of Telmisartan. This product is intended for research and analytical applications. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensinIIreceptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensinII-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure .
TD-0212 TFA is an orally active dual pharmacology angiotensinII type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP .
Telmisartan-d4 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
Telmisartan-d3 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
TD-0212 (compound 35) is an orally active dual pharmacology angiotensinII type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP .
Telmisartan- 13C,d3 is the 13C- and deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Candesartan (CV 11974) is an orally active angiotensinIIAT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
Olmesartan-d6 (RNH-6270-d6) is the deuterium labeled Olmesartan. Olmesartan (RNH-6270) is an angiotensinIIreceptor (AT1R) antagonist used to treat high blood pressure[1][2].
TRV056 is a Gq-biased ligand of the angiotensinIIreceptor type 1 (AT1R). TRV056 is efficacious in stimulating cellular Gq-mediated signaling. TRV056 can be used to develop the Gq-biased AT1R agonists .
Telmisartan-d7 (BIBR 277-d7) is a deuterium labeled Telmisartan (HY-13955). Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Candesartan Cilexetil (TCV-116) is an angiotensinIIreceptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure .
Antihypertensive agent 2 (Compound 4g) is an antihypertensive agent. Antihypertensive agent 2 has effective antagonistic activities against angiotensinIIreceptor 1. Antihypertensive agent 2 reduces the blood pressure with equal or more potency compared to Losartan (HY-17512) .
Losartan carboxylic acid-d4 (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensinIIreceptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensinII-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure[1][2][3][4].
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptorangiotensinII protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .
Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensinIIAT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
Azilsartan (TAK-536) is an orally active, potent, selective and specific angiotensinII type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research .
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensinIIreceptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensinII–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .
TRV120027, a β-arrestin-1-biased agonist of the angiotensinIIreceptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensinII–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
Apelin-13 is an endogenous ligand for the G-protein coupled receptorangiotensinII protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
Azilsartan mepixetil potassium (QR-01019K) is the antagonist of angiotensinIIreceptor. Azilsartan mepixetil potassium has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil potassium has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
Candesartan Cilexetil (Standard) is the analytical standard of Candesartan Cilexetil. This product is intended for research and analytical applications. Candesartan Cilexetil (TCV-116) is an angiotensinIIreceptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure .
Azilsartan-d4 is the deuterium labeled Azilsartan[1]. Azilsartan is an orally active, potent, selective and specific angiotensinII type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research[2][3][4][5][6].
AT2R antagonist 1 (compound 21) is a potent and high selective AT2R (angiotensinII AT2 receptor) ligand. AT2R antagonist 1 exhibits a fair AT2R affinity, with a Ki of 29 nM. AT2R antagonist 1 also inhibits common agent-metabolizing CYP enzymes. AT2R antagonist 1 shows high stability in human, rat and mouse liver microsomes .
KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 0.02 μM. KR-39038 significantly inhibits angiotensinII-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research .
AT2 receptor ligand-1(compound 14) is a potent angiotensin AT2 receptor ligand with the Ki 4.9 nM. AT2 receptor ligand-1 shows high stability in microsomes of the sulfonamide ligands .
Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensinII type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .
Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis .
Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is an antagonist of angiotensinIIreceptor (IC50=48.2 μM). Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is a quinolone alkaloid from Evodia rutaecarpa .
Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensinII type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .
1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, a quinolone alkaloid, is a diacylglycerol acyltransferase inhibitor and angiotensinIIreceptor blocker, with IC50s of 20.1 μM and 34.1 μM, respectively. 1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone shows potent anti-Helicobacter pylori activity with the MIC of 10 μg/mL .
AngiotensinII (AngiotensinII) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human also induces apoptosis. AngiotensinII induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII human (AngiotensinII) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human acetate also induces apoptosis. AngiotensinII human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII human (AngiotensinII) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human TFA also induces apoptosis. AngiotensinII human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII antipeptide, a peptide, is an inverse agonist of AR1 receptor. AngiotensinII antipeptide is encoded by mRNA, complementary to that encoding AngiotensinII (HY-13948) itself .
(Sar1)-AngiotensinII, an analogue of AngiotensinII, is a specific agonist of angiotensin AT1 receptor. (Sar1)-AngiotensinII binds to brain membrane-rich particles, with a Kd of 2.7 nM. (Sar1)-AngiotensinII can stimulate protein synthesis and cell growth in embryonic chick myocytes .
(Sar1,Ile4,8)-AngiotensinII is a functionally selective angiotensinII type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-AngiotensinII potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-AngiotensinII potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .
AngiotensinII (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensinII . AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
AngiotensinII (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
AngiotensinII (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
Saralasin ([Sar1,Ala8] AngiotensinII) acetate hydrate is an octapeptide analog of angiotensinII. Saralasin acetate hydrate is a competitive angiotensinIIreceptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
Saralasin ([Sar1,Ala8] AngiotensinII) TFA is an octapeptide analog of angiotensinII. Saralasin TFA is a competitive angiotensinIIreceptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
Aclerastide (DSC-127) is an angiotensinreceptor agonist. Aclerastide also is a peptide analog of angiotensinII. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers .
TRV055, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensinIIreceptor type 1 (AT1R). TRV055 is efficacious in stimulating cellular Gq-mediated signaling .
TRV055 hydrochloride, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensinIIreceptor type 1 (AT1R). TRV055 hydrochloride is efficacious in stimulating cellular Gq-mediated signaling .
TRV056 is a Gq-biased ligand of the angiotensinIIreceptor type 1 (AT1R). TRV056 is efficacious in stimulating cellular Gq-mediated signaling. TRV056 can be used to develop the Gq-biased AT1R agonists .
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptorangiotensinII protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensinIIreceptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensinII–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .
TRV120027, a β-arrestin-1-biased agonist of the angiotensinIIreceptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensinII–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
Apelin-13 is an endogenous ligand for the G-protein coupled receptorangiotensinII protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
AngiotensinII (AngiotensinII) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human also induces apoptosis. AngiotensinII induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is an antagonist of angiotensinIIreceptor (IC50=48.2 μM). Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is a quinolone alkaloid from Evodia rutaecarpa .
1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, a quinolone alkaloid, is a diacylglycerol acyltransferase inhibitor and angiotensinIIreceptor blocker, with IC50s of 20.1 μM and 34.1 μM, respectively. 1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone shows potent anti-Helicobacter pylori activity with the MIC of 10 μg/mL .
The NLRP6 protein serves as the central sensor of the NLRP6 inflammasome, driving inflammasome activation in response to various pathogen-related signals. It recognizes specific pathogen- and damage-associated signals, such as lipoteichoic acid (LTA) and double-stranded RNA (dsRNA), initiating liquid-liquid phase separation (LLPS) to form complexes. NLRP6 Protein, Human (Sf9) is the recombinant human-derived NLRP6 protein, expressed by Sf9 insect cells , with tag free. The total length of NLRP6 Protein, Human (Sf9) is 892 a.a., .
AngiotensinII human- 13C6, 15N TFA (Ang II- 13C6, 15N TFA) is 13C- and 15N-labeled AngiotensinII human (TFA) (HY-13948B). AngiotensinII human (AngiotensinII) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions .
Losartan-d4 is the deuterium labeled Losartan. Losartan is an angiotensinIIreceptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d3 Carboxylic Acid is the deuterium labeled Losartan. Losartan is an angiotensinIIreceptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d2 is the deuterium labeled Losartan[1]. Losartan is an angiotensinIIreceptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d9 is the deuterium labeled Losartan[1]. Losartan is an angiotensinIIreceptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Eprosartan-d3 is the deuterium labeled Eprosartan. Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensinIIreceptor antagonist, used as an antihypertensive. Eprosartan binds angiotensinIIreceptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively [1].
Irbesartan-d6 is the deuterium labeled Irbesartan. Irbesartan is a highly potent and specific angiotensinII type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensinIIreceptor antagonist and has the potential for high blood pressure and heart failure research[1].
Valsartan-d8 is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensinIIreceptor antagonist and has the potential for high blood pressure and heart failure research[1].
(Rac)-Valsartan-d9 is deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensinIIreceptor antagonist and has the potential for high blood pressure and heart failure research[1].
Valsartan-d3 is the deuterium labeled Valsartan[1]. Valsartan (CGP 48933) is an angiotensinIIreceptor antagonist and has the potential for high blood pressure and heart failure research[2].
Sparsentan-d5 is deuterium labeled Sparsentan. Sparsentan (RE-021) is a highly potent dual angiotensinII and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively[1].
Telmisartan-d4 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
Telmisartan-d3 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
Telmisartan- 13C,d3 is the 13C- and deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Olmesartan-d6 (RNH-6270-d6) is the deuterium labeled Olmesartan. Olmesartan (RNH-6270) is an angiotensinIIreceptor (AT1R) antagonist used to treat high blood pressure[1][2].
Telmisartan-d7 (BIBR 277-d7) is a deuterium labeled Telmisartan (HY-13955). Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Losartan carboxylic acid-d4 (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensinIIreceptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensinII-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure[1][2][3][4].
Azilsartan-d4 is the deuterium labeled Azilsartan[1]. Azilsartan is an orally active, potent, selective and specific angiotensinII type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research[2][3][4][5][6].